Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Wiedmann

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Nature Reviews. Cardiology|February 28, 2024
Novel drug therapies for atrial fibrillationFelix Wiedmann, Constanze Schmidt
Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik E.V|April 10, 2025
Disease mechanism and novel drug therapies for atrial fibrillationConstanze Schmidt, Felix Wiedmann
Herz|March 8, 2025
Precision medicine in the management of cardiac arrhythmiasFelix Wiedmann, Constanze Schmidt
Cells|November 27, 2021
Two-Pore-Domain Potassium (K<sub>2P</sub>-) Channels: Cardiac Expression Patterns and Disease-Specific Remodelling ProcessesFelix Wiedmann, Norbert Frey, Constanze Schmidt
The Journal of Physiology|April 12, 2024
Comment on: 'Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart' by Saint-Martin Willer et alMerten Prüser, Felix Wiedmann, Constanze Schmidt
Frontiers in Pharmacology|February 11, 2020
Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium ChannelsAntonius Ratte, Felix Wiedmann, Manuel Kraft, et al.
European Journal of Pharmacology|June 15, 2014
Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic conceptConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
Progress in Biophysics and Molecular Biology|June 20, 2020
Mechanosensitive TREK-1 two-pore-domain potassium (K<sub>2P</sub>) channels in the cardiovascular systemFelix Wiedmann, Susanne Rinné, Birgit Donner, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2018
New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K<sub>2P</sub>3.1 (TASK-1) ChannelsConstanze Schmidt, Felix Wiedmann, Anne-Rike Gaubatz, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 14, 2012
Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channelsConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Nature Reviews. Cardiology|February 28, 2024
Novel drug therapies for atrial fibrillationFelix Wiedmann, Constanze Schmidt
Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik E.V|April 10, 2025
Disease mechanism and novel drug therapies for atrial fibrillationConstanze Schmidt, Felix Wiedmann
Herz|March 8, 2025
Precision medicine in the management of cardiac arrhythmiasFelix Wiedmann, Constanze Schmidt
Cells|November 27, 2021
Two-Pore-Domain Potassium (K<sub>2P</sub>-) Channels: Cardiac Expression Patterns and Disease-Specific Remodelling ProcessesFelix Wiedmann, Norbert Frey, Constanze Schmidt
The Journal of Physiology|April 12, 2024
Comment on: 'Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart' by Saint-Martin Willer et alMerten Prüser, Felix Wiedmann, Constanze Schmidt
Frontiers in Pharmacology|February 11, 2020
Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium ChannelsAntonius Ratte, Felix Wiedmann, Manuel Kraft, et al.
European Journal of Pharmacology|June 15, 2014
Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic conceptConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
Progress in Biophysics and Molecular Biology|June 20, 2020
Mechanosensitive TREK-1 two-pore-domain potassium (K<sub>2P</sub>) channels in the cardiovascular systemFelix Wiedmann, Susanne Rinné, Birgit Donner, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2018
New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K<sub>2P</sub>3.1 (TASK-1) ChannelsConstanze Schmidt, Felix Wiedmann, Anne-Rike Gaubatz, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 14, 2012
Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channelsConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
Pageof 6